sorafenib has been researched along with labetalol in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (labetalol) | Trials (labetalol) | Recent Studies (post-2010) (labetalol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,980 | 450 | 327 |
| Protein | Taxonomy | sorafenib (IC50) | labetalol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.016 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.354 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.01 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.393 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.354 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.521 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.393 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.037 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.607 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.815 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Al-Ach, NN; Al-Tel, TH; Alshihabi, AM; Anbar, HS; El-Awady, R; El-Gamal, MI; El-Gamal, R; Kalla, RR; Munther, MA; Sbenati, RM; Shahin, AI; Shehata, MK; Tarazi, H; Tokatly, RT; Wahba, MM; Zaraei, SO | 1 |
1 review(s) available for sorafenib and labetalol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for sorafenib and labetalol
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydroxyquinolines; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Quinolines; Sorafenib; Structure-Activity Relationship | 2022 |